Aurobindo Pharma’s consolidated net profit increased 2 per cent to ₹921 crore in Q4 FY26 compared to ₹903 crore in the year-ago period.
The total revenue of the Hyderabad-based company grew 5.6 per cent to ₹8,853 crore (₹8,382 crore).
For FY26, net profit almost remained flat at ₹3,503 crore (₹3,484 crore), while the total revenue increased 6.1 per cent to ₹33,653 crore (₹31,724 crore).
“We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio,’’ K. Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, said in a release.
“Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilisation of recently-commercialised facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders,’’ Reddy added.
US revenue dips
The US revenue decreased 13 per cent to ₹3,543 crore, primarily due to lower transient sales and accounted for 40 per cent of consolidated revenue.
The revenue from Europe increased 30 per cent to ₹2,795 crore, driven by robust performance across all key markets; and accounted for 31.6 per cent of of consolidated revenue.